445 related articles for article (PubMed ID: 28841827)
1. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
2. Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China.
Liu S; Wang D; Chen F; Zhang X
BMC Ophthalmol; 2019 Jul; 19(1):157. PubMed ID: 31337360
[TBL] [Abstract][Full Text] [Related]
3. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
[TBL] [Abstract][Full Text] [Related]
4. One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
Li F; Zhang L; Wang Y; Xu W; Jiao W; Ma A; Zhao B
Curr Eye Res; 2018 Feb; 43(2):218-223. PubMed ID: 29265939
[TBL] [Abstract][Full Text] [Related]
5. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
Holbach B; Zeman F; Helbig H; Gamulescu MA
Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
[TBL] [Abstract][Full Text] [Related]
6. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
[No Abstract] [Full Text] [Related]
7. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Liu W; Li Y; Cao R; Bai Z; Liu W
Medicine (Baltimore); 2020 May; 99(21):e20222. PubMed ID: 32481293
[TBL] [Abstract][Full Text] [Related]
11. Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
Zhang W; Zhao G; Fan W; Zhao T
BMC Ophthalmol; 2021 Apr; 21(1):160. PubMed ID: 33789617
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
15. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.
Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Ponthieux A; Blin P; Grelaud A
Ophthalmic Res; 2019; 62(2):101-110. PubMed ID: 30928985
[TBL] [Abstract][Full Text] [Related]
17. The fellow eye effect of unilateral intravitreal conbercept injections in eyes with diabetic macular edema.
Di Y; Li Z; Ye J; Li L; Li B; Yu R
Acta Diabetol; 2020 Aug; 57(8):1001-1007. PubMed ID: 32215730
[TBL] [Abstract][Full Text] [Related]
18. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
Ozkaya A; Demir G; Kirmaci A
Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
[TBL] [Abstract][Full Text] [Related]
19. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
